Corporate Members
FDA and NCCN Approvals

---

NCCN Guidelines® Now Recommend a New
Treatment Option for Extensive-stage SCLC

Explore this new option

---

The FDA has approved a new indication for IMFINZI® (durvalumab), in combination with platinum containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is
indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer
(NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Approval was based on results from the Phase III, global, doubleblind, placebo-controlled AEGEAN trial.1

important safety information

important information

AEGEAN Order Set Template

---

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Now Approved
Breyanzi®—a CAR T cell therapy option for patients with R/R CLL or SLL2

---

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

​DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible

---

FDA has approved BOSULIF (bosutinib) for a new indication and has also approved a new formulation.   
 

---